Literature DB >> 25790325

Use of a dual lumen port for automated red cell exchange in adults with sickle cell disease.

Anuj Shrestha1, Zeeshan Jawa1, Kathryn L Koch1, Amy B Rankin1, Qun Xiang2, Anand Padmanabhan3,4, Matthew S Karafin3,4, Joshua J Field1,4.   

Abstract

Red cell exchange (RCE) is a common procedure in adults with sickle cell disease (SCD). Implantable dual lumen Vortex (DLV) ports can be used for RCE in patients with poor peripheral venous access. We performed a retrospective cohort study of RCE procedures performed in adults with SCD. The main objective of the study was to compare the inlet speed, duration of procedures and rate of complications performed through DLV ports to those performed through temporary central venous and peripheral catheters. Twenty-nine adults with SCD underwent a total of 318 RCE procedures. Twenty adults had DLV ports placed and 218 procedures were performed using DLV ports. Mean length of follow-up after DLV port placement was 397 ± 263 days. Six DLV ports were removed due to infection and 1 for malfunction after a mean of 171 ± 120 days. Compared to temporary central venous and peripheral catheters, DLV port procedures had a greater rate of procedural complications, a longer duration, and a lower inlet speed (all P < 0.01). When accounting for the maximum allowable inlet speed to avoid citrate toxicity, 40% of DLV port procedures were greater than 10% below maximum speed, compared to 7 and 14% of procedures performed through temporary central venous and peripheral catheters (P < 0.0001). In conclusion, DLV ports can be used for RCE in adults with SCD, albeit with more procedural complications and longer duration. The smaller internal diameter and longer catheter of DLV ports compared to temporary central venous catheters likely accounts for the differences noted.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  port; red cell exchange; sickle cell disease

Mesh:

Year:  2015        PMID: 25790325     DOI: 10.1002/jca.21393

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  2 in total

Review 1.  Spectra Optia® for Automated Red Blood Cell Exchange in Patients with Sickle Cell Disease: A NICE Medical Technology Guidance.

Authors:  Iain Willits; Helen Cole; Roseanne Jones; Kimberley Carter; Mick Arber; Michelle Jenks; Joyce Craig; Andrew Sims
Journal:  Appl Health Econ Health Policy       Date:  2017-08       Impact factor: 2.561

Review 2.  Venous Thromboembolism in Children with Cancer and Blood Disorders.

Authors:  Richard H Ko; Courtney D Thornburg
Journal:  Front Pediatr       Date:  2017-02-06       Impact factor: 3.418

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.